Mechanism of action
IGF-1 LR3 is a synthetic analog of native IGF-1, modified by glutamine→arginine substitution at position 3 and N-terminal extension of 13 amino acids. These modifications reduce binding to IGF-binding proteins (IGFBP) by approximately 70-80%, increasing bioactive fraction in circulation. The peptide activates the IGF-1R receptor (tyrosine kinase), activating PI3K/Akt/mTOR pathways (protein synthesis via p70S6K and 4E-BP1 phosphorylation) and PI3K/Akt/GSK3-β (protein degradation suppression via FOXO1). Half-life is extended (20-30 h vs 12-15 h for native IGF-1) with approximately 3-fold higher biological potency.
Research applications
• Muscle hypertrophy and hyperplasia: satellite cell activation, myonuclear accretion
• Protein synthesis and mTOR pathway regulation
• Muscle atrophy: modulation of MAFbx/atrogin-1 and MuRF1
• Myotube growth in vitro
Biological properties studied
• IGF-1R activation and PI3K/Akt/mTOR and GSK3-β pathways
• Stimulation of satellite cell proliferation
• Increased muscle fibre cross-sectional area
• Extended half-life and reduced IGFBP binding
• Purity: ≥99% (HPLC)
• Presentation: Lyophilized powder
• Storage: 2-8°C
• Recommended diluent: 0.6% acetic acid (AA) or bacteriostatic water per protocol
Research use only.
